表皮生长因子受体EGFR在肾细胞癌中的表达及意义  

EXPRESSION AND ITS CLINICAL SIGNIFICANCE OF EGFR IN RENAL CELL CARCINOMA

作　　者：邹泓[1] 庞丽娟[1] 胡文浩[1] 齐妍[1] 郭长军[1] 梁伟华[1] 李锋[1] 

机构地区：[1]新疆石河子大学医学院病理教研室.石河子 832002

出　　处：《现代预防医学》2011年第6期1072-1073,1085,共3页Modern Preventive Medicine

基　　金：国家自然科学基金(81060209);石河子大学高层次人才科研启动基金(RCZX200784),石河子大学“263”青年骨干教师资助项目(YX06016)

摘　　要：[目的]通过检测表皮生长因子受体EGFR在肾细胞癌中的表达,探讨它们与肾癌的发生、病理亚型、临床分期的关系。[方法]按2004年WHO肾细胞肿瘤分类标准对114例肾细胞癌分型,免疫组织化学方法检测114例肾癌石蜡标本中EGFR蛋白的表达,分析肿瘤的TNM分期并随访患者,进行统计学分析。[结果]EGFR在全组阳性率为51.8%(56/114)。在肾透明细胞癌中阳性率为54.5%(42/77),乳头状肾癌中阳性率为45.4%(5/11),肾嫌色细胞癌中表达50.0%(7/14),Xp11.2易位性肾癌中阳性率为60%(6/10),肾未分化癌中无表达(0/2),EGFR在各亚型、TNM各期间阳性率均无统计学差异。[结论]EGFR可能参与肾癌的发生发展,是否可对其选用EGFR受体抑制剂化疗值得探讨。[ Objective] To investigate the expression and its clinical significance of EGFR in renal cell carcinoma （RCC）, and explore the occurrence, sub-pathology type and clinic stages. [Methods] The renal-cell carcinoma was classifi- cation according to the WHO renal-cell carcinoma classification in 2004. The protein expression of EGFR in 114 RCC tissues was examined by immunohistochemical assay. The TNM classification was analyzed and related statistic analysis was taken. [ Resuits] study showed that the expression rate of EGFR in RCC was 51.8% （56/114）. The expression rates of EGFR in clear cell renal ceil carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal carcinoma associated with Xp11.2 gene fusions, and undifferentiated renal carcinoma were 54.5% （42/77）, 45.4% （5/I1）, 50.0% （7/14）, 60% （6/10） and 0% （0/2）, respectively. The differences of expression rate between different TNM I, II stage and TNM III, VI stage did not show statistical significance. [Conclusion] EGFR may play a role in developing of RCC.

关 键 词：肾肿瘤 癌 免疫组化 EGFR 

分 类 号：R737.11[医药卫生—肿瘤]